What you need to understand is that Momenta is a small development stage biopharmaceutical company. The have no responsibility for manufacturing and no expertise in it. I also doubt that Momenta is even in the loop regarding whatever remediation is ongoing. Most of the communication would be between Pfizer and the FDA. Sandoz should be qualifying a second source and I would hope to hear something about that in MNTAs next call. The impact on MNTA is far greater than the other players but it is in no way their fault.
Market Data 
Markets 
AI
